he American Society of Clinical Oncology’s annual Genitourinary Cancers Symposium (ASCO GU) is one of the most anticipated medical meetings for our Bladder Cancer, Prostate Cancer, and RCC disease areas, with clinical presentations providing landscape-altering updates for both early- and late-stage development. The ONCrg team of experts call upon their breadth and depth of knowledge to not only distill each abstract into key insights, but also provide meaningful context around the results.